![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RP Yasuda, W Ciesla, LR Flores, SJ Wall, M Li, SA Satkus, JS Weisstein, BV Spagnola and BB Wolfe
Department of Pharmacology, Georgetown University School of Medicine, Washington, D.C. 20007.
A portion of the cDNA sequence corresponding to the third intracellular loop of either the m4 or m5 muscarinic cholinergic receptor was ligated into the pRIT23 or pET-3a expression vector, respectively. The expressed fusion proteins were purified and used to develop selective polyclonal antisera to the m4 and m5 muscarinic receptors. These antisera were used in an immunoprecipitation protocol to examine quantitatively the distribution of receptor subtypes in regions of rat brain. The density of m4 receptors in rat brain increased in the caudal to rostral direction. The highest levels of m4 receptors were detected in the striatum (1280 fmol/mg) and olfactory tubercle (750 fmol/mg). Low levels of m5 receptors were detected in several brain regions (< 25 fmol/mg). By combining the previously determined receptor densities for the m1, m2, and m3 receptors and results obtained with the newly developed antisera to m4 and m5 receptors, it was determined that 86- 99% of the [3H]quinuclidinyl benzilate binding sites in several brain regions were immunoprecipitated. In addition to measuring receptor densities in rat brain, the immunoprecipitation protocol was used to quantify muscarinic receptor levels in tissues reported to express mRNA encoding the m4 receptor. Thus, although only m4 mRNA has been detected in rabbit lung, NG108-15 cells, and N1E-115 cells, both rabbit lung and NG108-15 cells possess both m2 (rabbit lung, 27%; NG108-15 cells, 31%) and m4 (rabbit lung, 55%; NG108-15, 42%) receptors, whereas N1E-115 cells were found to have both m1 (15%) and m4 (65%) receptors. These antisera will be useful in studies of receptor regulation and in determining alterations in density that may occur after pharmacological or physiological manipulations and in various disease states.
This article has been cited by other articles:
|
|
 |
|
  W. Y. Chan, D. L. McKinzie, S. Bose, S. N. Mitchell, J. M. Witkin, R. C. Thompson, A. Christopoulos, S. Lazareno, N. J. M. Birdsall, F. P. Bymaster, et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia PNAS, August 5, 2008; 105(31): 10978 - 10983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Liu, J. Li, D. T. H. Tan, and R. W. Beuerman Expression and Function of Muscarinic Receptor Subtypes on Human Cornea and Conjunctiva Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 2987 - 2996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Duttaroy, J. Gomeza, J.-W. Gan, N. Siddiqui, A. S. Basile, W. D. Harman, P. L. Smith, C. C. Felder, A. I. Levey, and J. Wess Evaluation of Muscarinic Agonist-Induced Analgesia in Muscarinic Acetylcholine Receptor Knockout Mice Mol. Pharmacol., November 1, 2002; 62(5): 1084 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Hemrick-Luecke, F. P. Bymaster, D. C. Evans, J. Wess, and C. C. Felder Muscarinic Agonist-Mediated Increases in Serum Corticosterone Levels Are Abolished in M2 Muscarinic Acetylcholine Receptor Knockout Mice J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 99 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Basile, I. Fedorova, A. Zapata, X. Liu, T. Shippenberg, A. Duttaroy, M. Yamada, and J. Wess Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia PNAS, August 20, 2002; 99(17): 11452 - 11457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang, M. Yamada, J. Gomeza, A. S. Basile, and J. Wess Multiple Muscarinic Acetylcholine Receptor Subtypes Modulate Striatal Dopamine Release, as Studied with M1-M5 Muscarinic Receptor Knock-Out Mice J. Neurosci., August 1, 2002; 22(15): 6347 - 6352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lezcano and C. Bergson D1/D5 Dopamine Receptors Stimulate Intracellular Calcium Release in Primary Cultures of Neocortical and Hippocampal Neurons J Neurophysiol, April 1, 2002; 87(4): 2167 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamada, K. G. Lamping, A. Duttaroy, W. Zhang, Y. Cui, F. P. Bymaster, D. L. McKinzie, C. C. Felder, C.-X. Deng, F. M. Faraci, et al. Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice PNAS, November 9, 2001; (2001) 251542998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Yeomans, J. Takeuchi, M. Baptista, D. D. Flynn, K. Lepik, J. Nobrega, J. Fulton, and M. R. Ralph Brain-Stimulation Reward Thresholds Raised by an Antisense Oligonucleotide for the M5 Muscarinic Receptor Infused near Dopamine Cells J. Neurosci., December 1, 2000; 20(23): 8861 - 8867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gomeza, L. Zhang, E. Kostenis, C. Felder, F. Bymaster, J. Brodkin, H. Shannon, B. Xia, C.-x. Deng, and J. Wess Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice PNAS, August 31, 1999; 96(18): 10483 - 10488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gomeza, H. Shannon, E. Kostenis, C. Felder, L. Zhang, J. Brodkin, A. Grinberg, H. Sheng, and J. Wess Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice PNAS, February 16, 1999; 96(4): 1692 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Olianas, A. Ingianni, C. Maullu, A. Adem, E. Karlsson, and P. Onali Selectivity Profile of Muscarinic Toxin 3 in Functional Assays of Cloned and Native Receptors J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 164 - 170. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. P. Caulfield and N. J. M. Birdsall International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors Pharmacol. Rev., June 1, 1998; 50(2): 279 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. v. d. Beukel, F. A. Dijcks, P. Vanderheyden, G. Vauquelin, and M. Oortgiesen J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1113 - 1119. [Abstract] [Full Text]
|
|
|
|
|
|
A. I. Levey Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease PNAS, November 26, 1996; 93(24): 13541 - 13546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Wolf, A. M. Wertkin, Y. C. Jolly, R. P. Yasuda, B. B. Wolfe, R. J. Konrad, D. Manning, S. Ravi, J. R. Williamson, and V. M.-Y. Lee Muscarinic Regulation of Alzheimer's Disease Amyloid Precursor Protein Secretion and Amyloid beta-Protein Production in Human Neuronal NT2N Cells J. Biol. Chem., March 3, 1995; 270(9): 4916 - 4922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamada, K. G. Lamping, A. Duttaroy, W. Zhang, Y. Cui, F. P. Bymaster, D. L. McKinzie, C. C. Felder, C.-X. Deng, F. M. Faraci, et al. Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice PNAS, November 20, 2001; 98(24): 14096 - 14101. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
